Olorofim Phase 3 Results Show Promise for Aspergillosis
The clinical trial met its primary endpoint, demonstrating non-inferiority compared to standard intravenous treatment.
Updated on Oct. 21, 2026 in Diseases — General
Live Poll
Do you support the development of novel antifungal medications for patients with limited treatment options?
F2G and Shionogi reported positive results from the Phase 3 OASIS study, which tested the investigational antifungal drug olorofim in patients with invasive aspergillosis. The oral medication met its primary endpoint of non-inferiority compared to standard intravenous treatment.
Why it matters
The study offers a potential new option for patients facing azole resistance, treatment failure, or severe drug-drug interactions. These results represent a significant step toward providing an oral alternative for a serious fungal infection.
In the Phase 3 trial, the olorofim group reported a 35.8% rate of drug-related adverse events, significantly lower than the 63.9% observed in the control group. Patients receiving olorofim also saw an average hospital discharge time of 17 days, compared to 28 days for the control.
The players
F2G
F2G is a biotechnology company headquartered in Manchester, United Kingdom, that specializes in the discovery and development of novel antifungal therapies.
Shionogi
Shionogi is a research-driven pharmaceutical company based in Osaka, Japan, focused on the development of medicines for infectious diseases.
The details
The OASIS study randomized 225 adult patients to receive either oral olorofim or intravenous AmBisome followed by standard care. Researchers administered 150 mg of olorofim twice daily on the first day, followed by a maintenance dose of 90 mg twice daily for up to 84 days.
Timeline
October 21, 2026: F2G and Shionogi announced the OASIS study results.
October 22, 2026: Study results presented at IDWeek 2026.
End of 2026: F2G plans to resubmit a New Drug Application to the FDA.
The Big Picture
The OASIS study provides a vital clinical benchmark for treating invasive aspergillosis in patients with documented azole resistance. These findings validate the potential for a new pharmacological class to fill critical gaps left by existing standard-of-care intravenous treatments.
The success of this oral treatment could eventually offer patients a shorter hospital stay compared to traditional intravenous options. This transition would potentially reduce the burden of long-term inpatient care for those managing invasive aspergillosis.
The takeaway
This trial underscores the growing importance of oral alternatives for patients suffering from fungal infections that have become resistant to traditional therapies. The data suggests that targeted antifungals may offer both improved safety profiles and reduced recovery times for patients.
What happens next
F2G expects to resubmit a New Drug Application to the U.S. Food and Drug Administration by the end of 2026.
Further reading
Learn more about evolving treatment protocols in Diseases — General.
More information
For further inquiries regarding the study, visit the Shionogi website inquiry form.
Live Poll
Do you support the development of novel antifungal medications for patients with limited treatment options?
